|
US20090191213A9
(en)
|
2003-07-02 |
2009-07-30 |
Novo Nordisk A/S |
Compositions and methods for regulating NK cell activity
|
|
HUE033129T2
(en)
|
2003-07-24 |
2017-11-28 |
Innate Pharma Sa |
Methods and compositions for increasing the efficacy of therapeutic antibodies using compounds that potentiate NK cells
|
|
WO2005105849A1
(en)
*
|
2004-04-30 |
2005-11-10 |
Innate Pharma |
Compositions and methods for treating proliferative disorders such as nk-type ldgl
|
|
CA2601417C
(en)
*
|
2004-07-01 |
2018-10-30 |
Novo Nordisk A/S |
Human anti-kir antibodies
|
|
ES2678094T3
(es)
|
2004-07-10 |
2018-08-08 |
Fox Chase Cancer Center |
Líneas de células asesinas naturales genéticamente modificadas
|
|
JP5525689B2
(ja)
*
|
2004-11-02 |
2014-06-18 |
ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
過剰増殖性障害を処置するための組成物および方法
|
|
JP5295568B2
(ja)
|
2005-01-06 |
2013-09-18 |
ノヴォ ノルディスク アー／エス |
Ｋｉｒ結合剤およびその使用方法
|
|
US20090196850A1
(en)
|
2005-01-06 |
2009-08-06 |
Novo Nordisk A/S |
Anti-Kir Combination Treatments and Methods
|
|
PL1835937T3
(pl)
|
2005-01-06 |
2012-09-28 |
Novo Nordisk As |
Kompozycje i sposoby leczenia infekcji wirusowej
|
|
GT200600148A
(es)
*
|
2005-04-14 |
2006-11-22 |
|
Metodos para el tratamiento y la prevencion de fibrosis
|
|
EP1934260B1
(en)
*
|
2005-10-14 |
2017-05-17 |
Innate Pharma |
Compositions and methods for treating proliferative disorders
|
|
AU2008204433B2
(en)
|
2007-01-11 |
2014-03-13 |
Novo Nordisk A/S |
Anti-KIR antibodies, formulations, and uses thereof
|
|
US8709411B2
(en)
*
|
2008-12-05 |
2014-04-29 |
Novo Nordisk A/S |
Combination therapy to enhance NK cell mediated cytotoxicity
|
|
US20120009148A1
(en)
*
|
2008-12-29 |
2012-01-12 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
|
|
JP5766619B2
(ja)
*
|
2010-02-08 |
2015-08-19 |
株式会社日本バイオセラピー研究所 |
Ｎｋ細胞強化型血液製剤の製造方法
|
|
CA2818684C
(en)
|
2010-11-22 |
2023-02-21 |
Innate Pharma Sa |
Nk cell modulating treatments and methods for treatment of hematological malignancies
|
|
US9067997B2
(en)
*
|
2011-05-25 |
2015-06-30 |
Innate Pharma Sa |
Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders
|
|
WO2012175613A1
(en)
|
2011-06-21 |
2012-12-27 |
Innate Pharma |
NKp46-MEDIATED NK CELL TUNING
|
|
JO3370B1
(ar)
*
|
2011-11-10 |
2019-03-13 |
Regeneron Pharma |
طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
|
|
WO2013076139A1
(en)
*
|
2011-11-23 |
2013-05-30 |
F. Hoffmann-La Roche Ag |
Cd40l expressing mammalian cells and their use
|
|
RU2682449C2
(ru)
*
|
2012-09-19 |
2019-03-19 |
Иннейт Фарма |
Связывающие kir3dl2 агенты
|
|
BR112015007184A2
(pt)
|
2012-10-02 |
2017-08-08 |
Bristol Myers Squibb Co |
combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer
|
|
EP3066128B1
(en)
|
2013-11-06 |
2018-10-31 |
Bristol-Myers Squibb Company |
Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
|
|
US10429394B2
(en)
|
2014-08-29 |
2019-10-01 |
National University Corporation Hokkaido |
Monoclonal antibodies against KIR2DS1
|
|
US11639384B2
(en)
|
2014-10-28 |
2023-05-02 |
University Children's Hospital Tübingen |
Treatment of pediatric BCP-ALL patients with an anti-KIR antibody
|
|
HRP20220890T1
(hr)
|
2015-02-06 |
2022-10-14 |
National University Of Singapore |
Postupci za povećanje učinkovitosti terapijskih imunosnih stanica
|
|
HRP20201334T1
(hr)
|
2015-04-17 |
2020-11-27 |
Bristol-Myers Squibb Company |
Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
|
|
WO2016177682A1
(en)
|
2015-05-06 |
2016-11-10 |
Snipr Technologies Limited |
Altering microbial populations & modifying microbiota
|
|
EP3297672B1
(en)
|
2015-05-21 |
2021-09-01 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
MX2017016844A
(es)
|
2015-07-16 |
2018-08-15 |
Biokine Therapeutics Ltd |
Composiciones y procedimientos para tratar cancer.
|
|
PT3370768T
(pt)
|
2015-11-03 |
2022-04-21 |
Janssen Biotech Inc |
Anticorpos que se ligam especificamente ao pd-1 e seus usos
|
|
US20190038713A1
(en)
|
2015-11-07 |
2019-02-07 |
Multivir Inc. |
Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
HRP20220237T1
(hr)
|
2016-05-20 |
2022-04-29 |
Biohaven Therapeutics Ltd. |
Primjena riluzola, prolijekova riluzola ili analoga riluzola sa imunoterapijama za liječenje raka
|
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
|
US20190233534A1
(en)
|
2016-07-14 |
2019-08-01 |
Fred Hutchinson Cancer Research Center |
Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
|
|
GB201616365D0
(en)
*
|
2016-09-27 |
2016-11-09 |
Helsingin Yliopisto |
Non-genetic modification of enveloped viruses
|
|
EP3518946A4
(en)
|
2016-09-27 |
2020-09-09 |
Board of Regents, The University of Texas System |
METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME
|
|
WO2018071668A1
(en)
|
2016-10-12 |
2018-04-19 |
Board Of Regents, The University Of Texas System |
Methods and compositions for tusc2 immunotherapy
|
|
WO2018073363A1
(en)
|
2016-10-21 |
2018-04-26 |
Innate Pharma |
Treatment with anti-kir3dl2 agents
|
|
WO2018111902A1
(en)
|
2016-12-12 |
2018-06-21 |
Multivir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
|
EP3601355A1
(en)
|
2017-03-31 |
2020-02-05 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
KR102009040B1
(ko)
|
2017-04-05 |
2019-08-08 |
한국생명공학연구원 |
Nk 세포 활성화 융합 단백질, nk 세포 및 이들을 포함하는 약제학적 조성물
|
|
SG10202107880XA
(en)
|
2017-05-12 |
2021-09-29 |
Harpoon Therapeutics Inc |
Mesothelin binding proteins
|
|
WO2018218207A1
(en)
|
2017-05-26 |
2018-11-29 |
Fred Hutchinson Cancer Research Center |
Anti-cd33 antibodies and uses thereof
|
|
CN107261304A
(zh)
*
|
2017-06-05 |
2017-10-20 |
中国兽医药品监察所 |
一种奶牛的布鲁氏菌病免疫试剂盒及其应用
|
|
CA3071282A1
(en)
|
2017-08-10 |
2019-02-14 |
National University Of Singapore |
T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
CA3078969A1
(en)
|
2017-10-13 |
2019-04-18 |
Harpoon Therapeutics, Inc. |
Trispecific proteins and methods of use
|
|
EP3694884A1
(en)
|
2017-10-15 |
2020-08-19 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
CN108060137B
(zh)
*
|
2017-12-26 |
2021-07-02 |
博生吉医药科技(苏州)有限公司 |
Il7和il21修饰的nk92细胞、制备方法及其应用
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
CA3090244A1
(en)
|
2018-02-08 |
2019-08-15 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting the nkg2d receptor
|
|
MX2020008333A
(es)
|
2018-02-08 |
2020-09-21 |
Dragonfly Therapeutics Inc |
Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
|
|
CN112119093A
(zh)
|
2018-02-20 |
2020-12-22 |
蜻蜓治疗公司 |
结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
|
|
CA3094329A1
(en)
|
2018-03-19 |
2020-02-20 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
|
|
JP7351845B2
(ja)
|
2018-03-23 |
2023-09-27 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
|
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
|
CA3094458A1
(en)
|
2018-03-25 |
2019-10-31 |
Snipr Biome Aps. |
Treating & preventing microbial infections
|
|
EP3774911A1
(en)
|
2018-03-30 |
2021-02-17 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
JP7584299B2
(ja)
|
2018-05-23 |
2024-11-15 |
ナショナル ユニバーシティ オブ シンガポール |
Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ２表面発現の遮断およびキメラ抗原受容体の発現
|
|
CN113164570B
(zh)
|
2018-08-08 |
2024-05-14 |
蜻蜓疗法股份有限公司 |
结合nkg2d、cd16和肿瘤相关抗原的蛋白质
|
|
CA3108427A1
(en)
|
2018-08-08 |
2020-02-13 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
EP3849565A4
(en)
|
2018-09-12 |
2022-12-28 |
Fred Hutchinson Cancer Research Center |
REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
CN119306844A
(zh)
|
2018-09-25 |
2025-01-14 |
哈普恩治疗公司 |
Dll3结合蛋白及使用方法
|
|
AU2019384816A1
(en)
|
2018-11-21 |
2021-06-24 |
Board Of Regents, The University Of Texas System |
Methods and compositions for treating cancer
|
|
BR112021012066A2
(pt)
|
2018-12-21 |
2021-11-03 |
Onxeo |
Novas moléculas de ácido nucleico conjugadas e seus usos
|
|
WO2020243570A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
JP2022534982A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル－マイヤーズ スクイブ カンパニー |
細胞局在化シグネチャーおよびその使用
|
|
US20220363760A1
(en)
|
2019-05-30 |
2022-11-17 |
Bristol-Myers Squibb Company |
Multi-tumor gene signature for suitability to immuno-oncology therapy
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
|
CN111424012A
(zh)
*
|
2020-03-30 |
2020-07-17 |
威海市中心医院 |
一种nk细胞培养用的饲养细胞去增殖能力的处理方法
|
|
CA3173213A1
(en)
|
2020-03-31 |
2021-10-07 |
Roland B. WALTER |
Anti-cd33 antibodies and uses thereof
|
|
AU2021268340A1
(en)
|
2020-05-06 |
2022-12-08 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16 and CLEC12A
|
|
AR122644A1
(es)
|
2020-06-19 |
2022-09-28 |
Onxeo |
Nuevas moléculas de ácido nucleico conjugado y sus usos
|
|
CN116234568A
(zh)
|
2020-07-07 |
2023-06-06 |
生物技术公司 |
用于hpv阳性癌症的治疗性rna
|
|
IL300916A
(en)
|
2020-08-31 |
2023-04-01 |
Bristol Myers Squibb Co |
Cell localization signature and immunotherapy
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
WO2022140755A1
(en)
*
|
2020-12-23 |
2022-06-30 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Inhibition of kir2dl2 for the enhancement of adoptive immunotherapies
|
|
PT4267105T
(pt)
|
2020-12-28 |
2025-04-30 |
Bristol Myers Squibb Co |
Composições de anticorpos e métodos de utilização das mesmas
|
|
AU2021416156A1
(en)
|
2020-12-28 |
2023-06-22 |
Bristol-Myers Squibb Company |
Methods of treating tumors
|
|
AU2022218137A1
(en)
|
2021-02-03 |
2023-08-24 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
|
EP4301774A4
(en)
|
2021-03-03 |
2025-08-13 |
Dragonfly Therapeutics Inc |
METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
|
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型ｃｄｃｐ１に対する抗体およびその使用
|
|
WO2023285552A1
(en)
|
2021-07-13 |
2023-01-19 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
|
WO2023059333A1
(en)
|
2021-10-08 |
2023-04-13 |
3M Innovative Properties Company |
Slot die assembly with tuned stiffness, reduced draw zone, and force budget
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
WO2023110937A1
(en)
|
2021-12-14 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
|
CA3240558A1
(en)
|
2021-12-16 |
2023-06-22 |
Valerio Therapeutics |
New conjugated nucleic acid molecules and their uses
|
|
US20250206775A1
(en)
|
2022-03-18 |
2025-06-26 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
|
AU2023281061A1
(en)
|
2022-06-02 |
2024-12-05 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
GB202209518D0
(en)
|
2022-06-29 |
2022-08-10 |
Snipr Biome Aps |
Treating & preventing E coli infections
|
|
WO2024026385A1
(en)
*
|
2022-07-28 |
2024-02-01 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Inhibition of kir2dl2 and/or kir2dl3 for the enhancement of adoptive immunotherapies
|
|
TW202426486A
(zh)
*
|
2022-10-25 |
2024-07-01 |
日商第一三共股份有限公司 |
使用針對抑制型ｋｉｒ的促效劑的免疫排斥之迴避方法
|
|
JP2026501506A
(ja)
|
2022-12-14 |
2026-01-16 |
アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ |
Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
|
|
CN121712571A
(zh)
|
2023-08-15 |
2026-03-20 |
百时美施贵宝公司 |
陶瓷羟基磷灰石色谱流通法
|
|
AR134560A1
(es)
|
2023-12-08 |
2026-01-28 |
Astellas Pharma Inc |
Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2
|
|
WO2026033885A1
(en)
|
2024-08-08 |
2026-02-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
CN122459678A
(zh)
|
2023-12-29 |
2026-07-24 |
百时美施贵宝公司 |
KRAS抑制剂与Treg耗竭剂的组合疗法
|
|
CN117883553B
(zh)
*
|
2024-01-12 |
2024-08-27 |
成都医学院 |
Pml-1蛋白在制备抑制细胞因子风暴的药物中的应用
|